1. Association of gout with CAD and effect of antigout therapy on CVD risk among gout patients
- Author
-
Kuang-Hsi Chang, Wei-Shih Huang, Chon-Haw Tsai, and Cheng-Li Lin
- Subjects
musculoskeletal diseases ,Adult ,Male ,medicine.medical_specialty ,congenital, hereditary, and neonatal diseases and abnormalities ,Gout ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,Lower risk ,coronary disease ,General Biochemistry, Genetics and Molecular Biology ,Gout Suppressants ,Coronary artery disease ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Risk Factors ,Internal medicine ,medicine ,Clinical endpoint ,Humans ,Hyperuricemia ,cardiovascular diseases ,Risk factor ,Original Research ,Aged ,030203 arthritis & rheumatology ,business.industry ,Incidence ,Confounding ,nutritional and metabolic diseases ,General Medicine ,Middle Aged ,medicine.disease ,Cohort ,Female ,business - Abstract
Hyperuricemia has been identified as an independent risk factor for coronary artery disease (CAD), with a dose-response association. In this study, we explored the causal association between gout and antigout medication and the risk of incidental CAD. We sampled data from the National Health Insurance Research Database and recruited 37,091 patients as the gout cohort, and 37,091 controls. Our primary endpoint was the diagnosis of CAD during follow-up. The overall study population was followed up until CAD diagnosis, withdrawal from the National Health Insurance program, or the end of the study. Cox proportional hazards regression models were used to examine the effect of gout on the risk of CAD, represented by the HR with the 95% CI. Patients with gout were at greater risk of CAD, compared with those without gout: HR=1.49 after adjusting for potential confounders. Non-steroidal anti-inflammatory drugs and prednisolone use was associated with a reduced risk of CAD: HR=0.63 and 0.50, respectively. Patients with gout, treated with antigout medication, exhibited a reduced risk of CAD compared with non-gout patients. Among patients with gout, those on antigout therapy had 32% lower risk compared with those not on antigout therapy: adjusted HR=0.68, 95% CI 0.63 to 0.73. Gout increases the risk of CAD, and the use of antigout medication reduces CAD risk. These results indicate that gout or hyperuricemia is a modifiable risk factor for CAD.
- Published
- 2020